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Introduction {#sec004}
============

Despite the availability of potent antivirals and vaccination against the hepatitis B virus (HBV), chronic HBV infection remains a significant socioeconomic burden. The global prevalence of chronic HBV in 2016 was close to 3.9%, which equates to approximately 292 million HBsAg-positive individuals, making it one of the most common human pathogens, and there is large regional variation\[[@pone.0227532.ref001]\]. In addition to its effects on the liver, patients with HBV have extrahepatic manifestations of renal disease. In a single-center retrospective trial, Zhang et al\[[@pone.0227532.ref002]\] reported that 3% (n = 352) of a total of 11,618 kidney biopsies performed from 1987 to 2012 in Beijing, China, were HBV-GN positive.

Treatment of HBV-GN remains a challenge for clinicians, the use of steroids or immunity inhibitors is still controversial because of the risk of activating viral infections, so the mainstay of treatment continues to be antiviral therapy. Several drugs are now available for the treatment of chronic HBV infection and are mainly one of two types: nucleos (t) ide analogs (NAs), such as lamivudine, adefovir, entecavir, telbivudine, and tenofovir, and interferons (IFNs)\[[@pone.0227532.ref003]\]. However, their efficacy and safety remain poorly established and uncertain.

Several meta-analyses\[[@pone.0227532.ref004]--[@pone.0227532.ref010]\] have been published regarding the effects of different therapies in HBV-GN patients; three studies\[[@pone.0227532.ref004],[@pone.0227532.ref006],[@pone.0227532.ref007]\] focused on the effects of antiviral treatment on HBV-GN but were completed before 2011. However, previous investigators did not provide details regarding to therapies, such as treatment for patients of different ages, antiviral drug selection or treatment duration. Standardized treatment guidelines that are personalized and appropriate for the current therapeutic regimen are lacking. Therefore, we performed an updated systematic review of clinical trials to evaluate the efficacy of antiviral therapy for HBV-GN.

Methods {#sec005}
=======

We performed our meta-analysis as suggested by the Cochrane guidelines\[[@pone.0227532.ref011]\]. The PRISMA (Preferred Reporting Items of Systematic reviews and Meta-Analyses) checklist was used to standardize the details\[[@pone.0227532.ref012]\], and the PRISMA checklist is shown in [S1 Table](#pone.0227532.s006){ref-type="supplementary-material"}. The protocol and registration information are available at <http://www.crd.york.ac.uk/PROSPERO/> (registration number: CRD42019125268).

1. Search strategy {#sec006}
------------------

We searched PUBMED, MEDLINE (Ovid Online), Embase and the Cochrane Library from inception to March 11^th^ 2019. We also searched for related terms using the medical subject headings (MeSH) database. The key words were \"interferon\", \"nucleoside analogs\", \"anti-viral\", \"lamivudine\", \"adefovir dipivoxil\", \"entecavir\", \"telbivudine\", \"hepatitis B virus\", \"glomerulonephritis\", and their synonyms and related terms. We also manually checked the reference lists of nephrology textbooks, review articles and reports from academic congresses.

2. Eligibility criteria {#sec007}
-----------------------

Trials were selected based on the following inclusion criteria:

1.  Randomized controlled trials (RCTs) and cohort clinical trials (CCTs) in which the intervention was antiviral therapy (IFN or NAs) were included. All studies had a follow-up period of at least 6 months and had been published in a journal.

2.  All included patients were diagnosed histologically based on the existence of HBeAg, HBcAg, or HBV-DNA in renal biopsy specimens, accompanied with HBV surface antigen (HBsAg)-positive serum and were free from lupus nephritis and other secondary glomerular diseases\[[@pone.0227532.ref013]\].

Clinical trials meeting the following criteria were excluded:

1.  Self-control studies or case reports.

2.  Patients who were diagnosed with glomerulonephritis but not secondary nephritis caused by the hepatitis B virus.

3. Selection of studies and data extraction {#sec008}
-------------------------------------------

All articles identified in the search were screened independently by two authors (Baohui Fu and Yue Ji) and deemed eligible if they met all inclusion and exclusion criteria. Any discrepancies were resolved by an expert (Shouci Hu). The references from all eligible articles were screened and included using the same process as above.

Data on the study (year, country, authorship, journal, study design and number of participants), demographic characteristics (glomerulonephritis status, age, sex, ethnicity, and pathological type of renal biopsy), intervention details (provider, doses and modalities of treatment, placebo group set up, duration of intervention, follow-up interval and follow-up duration), and outcomes (including laboratory reports: complete remission (CR) and partial remission (PR) of proteinuria; estimated glomerular filtration rate (eGFR); HBeAg clearance; adherence status and adverse drug reactions) were extracted from eligible articles independently by Baohui Fu and Yue Ji.

4. Risk of bias assessments {#sec009}
---------------------------

Two independent reviewers (Baohui Fu and Yue Ji) evaluated the risk of bias, when they disagreed, a third author (Shouci Hu) was involved; the three reviewers discussed the article until all reviewers reached a unified conclusion. We evaluated the quality of the RCTs with the Cochrane Collaboration's tool for assessing risk of bias for RCTs\[[@pone.0227532.ref011]\], and the cohort studies were evaluated with Newcastle−Ottawa scales\[[@pone.0227532.ref014]\].

5. Statistical analysis {#sec010}
-----------------------

Treatment effects were calculated as odds ratios (ORs) with 95% confidence intervals (CIs) to assess dichotomous outcomes. The mean differences (MDs) were used to evaluate the differences of continuous data. The standard deviation (SD) of changes were calculated according to the formula in Cochrane investigator\'s handbook 5.1.0, the value of correlation coefficient (Corr) was 0.5**\[[@pone.0227532.ref011]\]**. The heterogeneity test was performed using the chi-square test (χ^**2**^) and the I^2^statistic, where I^**2**^\>50% indicated significant heterogeneity**\[[@pone.0227532.ref015]\]**. In the presence of statistically significant heterogeneity (I^**2**^\>50%), the Mantel-Haenszel method in the random-effect model was selected; if I^**2**^\<50%, the fixed-effect model was used for the meta-analysis**\[[@pone.0227532.ref016]\]**. A sensitivity analysis or subgroup analysis was used to discover heterogeneity. Publication bias was assessed by Egger's test and Begg's test. All statistical analyses were performed using RevMan 5.3 (Cochrane Collaboration, Oxford, England). The sensitivity analyses and publication bias assessment were performed using STATA 13.1 (Stata Corp., College Station, Texas, USA). When original data were not mentioned in the article but were found presented in reports and references as functional X-Y type scatter or line plots, Plot Digitizer 2.6.8.0 was used to digitize scanned plots of the functional data. Subgroup analyses were planned to explore potential sources of variability in the observed treatment effects. When possible, subgroup analyses were performed for clinical trial types, antiviral drug types, age and follow-up duration.

6. Study outcome measures {#sec011}
-------------------------

The primary outcomes that this systematic review focused on were renal remission rate and estimated glomerular filtration rate (eGFR), and the secondary outcome measure was HBeAg clearance. Complete remission (CR) of proteinuria was defined as urinary protein excretion less 0.3 g in 24 hours. Partial remission (PR) represented a decline in urinary protein excretion by 50% or a decline below the baseline value with an absolute amount greater than 0.3 g in 24 hours. Virologic response was defined as clearance of HBeAg from serum. These definitions are the standard definitions used in the current scientific literature.

Results {#sec012}
=======

1. Summary of included studies {#sec013}
------------------------------

We identified 334 potentially eligible records according to the search strategy. The selection process is illustrated in [Fig 1](#pone.0227532.g001){ref-type="fig"}. The titles and abstracts of these records were screened for inclusion, and 66 studies met the inclusion criteria. Based on our exclusion criteria, 56 of these studies were excluded after the full-text screening ([Fig 1](#pone.0227532.g001){ref-type="fig"}).

![Flow chart of study selection.](pone.0227532.g001){#pone.0227532.g001}

Finally, seven trials, involving 182 participants, were included in our study. Six of the articles were CCTs \[17−22\], and one was an RCT \[[@pone.0227532.ref023]\]; they included 44 females and 138 males. In addition, all the HBV-GN patients had kidney biopsies; membranous nephropathy (MN) was found in 134 patients (73.6%), followed by IgA nephropathy in 24 (13.2%), membranoproliferative glomerulonephritis (MPGN) in 12 (6.6%), focal segmental glomerulosclerosis (FSGS) in four, other pathological types, such as mesangial proliferative glomerulonephritis (MSPGN) and minimal change nephropathy (MCGP), in two patients and IgM nephropathy in one patient. Two patients had combined lesions, with one having a combination of MN and MPGN and the other having FSGS and IgAN. The characteristics are described in [Table 1](#pone.0227532.t001){ref-type="table"}.

10.1371/journal.pone.0227532.t001

###### Characteristics of the included trials.

![](pone.0227532.t001){#pone.0227532.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                      Year   Region                 Study design   Mean age (y)   Sex         Intervention                                                                                        Control                                               Duration   Follow-up             Dropo\   Outcomes
                                                                                                                                                                                                                                                                                                                ut       
  ------------------------------------------ ------ ---------------------- -------------- -------------- ----------- --------------------------------------------------------------------------------------------------- ----------------------------------------------------- ---------- --------------------- -------- ----------
  Sun et al\[[@pone.0227532.ref017]\]        2017   Shanghai               CCT            42.8±13.2      M:28 F:10   LAM (100 mg/day\                                                                                    ACEI/ARB alone (n = 18)                               12 mo      12 mo                 0        ①②
                                                                                                                     orally)+ACEI/ARB (n = 20)                                                                                                                                                                           

  Bhimma et al\[[@pone.0227532.ref018]\]     2002   Durban, South Africa   CCT            8.9            M:34 F:5    IFN-α2b (10 million units/m2 3 times/week)(n = 19)                                                  control of edema and hypertension (n = 20)            16 weeks   40 weeks              5        ①②③

  Tang et al\[[@pone.0227532.ref019]\]       2005   Hong Kong, China       CCT            45.5±19.0      M:14 F:8    LAM 100mg/d+ACEI or ARB (n = 10)                                                                    ACEI/ARB (n = 12)                                     NA         49.2±16.5 mo          0        ①③

  Panomsak et al\[[@pone.0227532.ref020]\]   2006   Thailand               CCT            40.9           M:10 F:7    1 month of prednisone, then 6 had LAM and 1 had IFN-α (n = 7)                                       ACEI, fish oil, or neither (n = 10)                   NA         5--120 mo             3        ①

  Sun et al\[[@pone.0227532.ref021]\]        2012   Seoul, Korea           CCT            37             M:9 F:1     Antiviral drugs (n = 6)                                                                             ACEI or ARB (n = 4)                                   NA         mean 87 mo (8--187)   1        ①

  Lai et al\[[@pone.0227532.ref022]\]        1991   Hong Kong, China       CCT            30             M:14 F:2    IFN-α2b (3 million units, 3 times/week, subcutaneous injection)(n = 5)                              diuretic agents/dipyridamole /no treatment (n = 11)   12 weeks   55.1 mo               0        ①②③

  Lin et al\[[@pone.0227532.ref023]\]        1995   Taiwan, China          RCT            6.5±3.3        M:29 F:11   IFN-α2b (5μ if body weight\<20 kg, 8μ if body weight\>20 kg, 3 times/week subcutaneous injection)   control\                                              12 mo      24 mo                 0        ③
                                                                                                                                                                                                                         of edema and hypertension                                                                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: RCT, randomized controlled trial; CCT, cohort clinical trial; M, male; F, female; LAM, lamivudine; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blocker; NA, not available; mo, months; ①Renal remission; ②eGFR (estimated glomerular filtration rate); ③HBeAg clearance.

2. Risk of bias assessments {#sec014}
---------------------------

The only RCT\[[@pone.0227532.ref023]\] in our analysis was low risk in terms of random sequence generation, blinding of participants and personnel, blinding of outcome assessment and incomplete outcome data but had an unclear risk with respect to allocation concealment, selective reporting and other bias ([S2 Fig](#pone.0227532.s002){ref-type="supplementary-material"}). The biases of the observational cohort studies, evaluated by the Newcastle−Ottawa scale, are shown in [Table 2](#pone.0227532.t002){ref-type="table"}. Three studies had seven to eight stars, which indicates very good quality; four studies had five to six stars and are regarded as being of good quality. After reading the clinical trial designs and protocols of the included literature in detail, no reporting biases were found.

10.1371/journal.pone.0227532.t002

###### Newcastle−Ottawa scale for the observational studies.

![](pone.0227532.t002){#pone.0227532.t002g}

  Study                                       Year   Selection (up to 4)   Comparability (up to 2)   Outcome (up to 3)
  ------------------------------------------- ------ --------------------- ------------------------- -------------------
  Sun et al.\[[@pone.0227532.ref017]\]        2017   3                     1                         2
  Bhimma et al.\[[@pone.0227532.ref018]\]     2002   3                     1                         2
  Tang et al.\[[@pone.0227532.ref019]\]       2005   3                     1                         3
  Panomsak et al.\[[@pone.0227532.ref020]\]   2006   3                     0                         2
  Sun et al.\[[@pone.0227532.ref021]\]        2012   3                     1                         3
  Lai et al.\[[@pone.0227532.ref022]\]        1991   2                     1                         3

3. Effects on proteinuria remission {#sec015}
-----------------------------------

### 3.1 Subgroup analysis of the association between efficacy and study type {#sec016}

Seven studies, involving 182 patients, evaluated the efficacy of antiviral therapy for HBV-GN. We evaluated the CR and total remission (CR+PR) rates after treatment with a fixed-effect model ([Fig 2](#pone.0227532.g002){ref-type="fig"}). There was no clinical and statistical heterogeneity in total remission of all trials (I^2^ = 0%, *P* = 0.80), and the test for the overall effect was significant (*P*\<0.00001). The total remission rate of proteinuria was obviously higher in the antiviral treatment group than in the control group in all studies (OR = 10.48, 95% CI: 4.60−23.89). The antiviral treatment significantly affected CR in all trials (OR = 11.64, 95% CI: 5.17−26.21). There was no heterogeneity between data sources in the CR of all trials (I^2^ = 23%, P = 0.26). The χ^2^ test of heterogeneity was not significant in the CR evaluation from the CCTs (I^2^ = 9%, *P* = 0.36, OR = 8.47, 95% CI: 3.67−20.80). We conducted a sensitivity analysis of all studies ([S3 Fig](#pone.0227532.s003){ref-type="supplementary-material"}). Our analysis determined that the study by Sun's study\[[@pone.0227532.ref017]\] and Panomsak's study\[[@pone.0227532.ref020]\] was the source of heterogeneity.

![CR and CR+PR with antiviral therapy in all trials and CCTs.\
OR: odds ratio; CR: complete remission; PR: partial remission.](pone.0227532.g002){#pone.0227532.g002}

### 3.2 Subgroup analysis of the association between efficacy and antiviral drug type {#sec017}

To compare the effects of IFNs and NAs, we analyzed two subgroups. NA treatment for HBV-GN was assessed in 4 studies, and IFN treatment was assessed in 3 studies. Panomsak's\[[@pone.0227532.ref020]\] study included only one patient treated with IFNs, therefore, because groups could not be formed with only one patient, we removed this data when the statistical analyses were performed. Proteinuria was significantly decreased in the NA group (OR = 6.67, 95% CI: 2.50−17.80) and the IFN group (OR = 38.76, 95% CI: 7.03−213.71, [Fig 3](#pone.0227532.g003){ref-type="fig"}). Heterogeneity, calculated using the I^2^ statistic with a fixed-effect model, was I^2^ = 0%, *P* = 0.58 in the IFN group, and I^2^ = 1%, *P* = 0.39 in the NA group.

![CR and CR+PR with IFNs and NAs in HBV-GN patients.\
OR: odds ratio; CR: complete remission.](pone.0227532.g003){#pone.0227532.g003}

### 3.3 Subgroup analysis of the association between efficacy and age {#sec018}

Six studies included adult patients, and the other two studies included pediatric patients. The adult group had 103 patients, composing 56.6% of the total 182 patients, and the pediatric group had 79 patients, accounting for 43.4%. A fixed-effect model was used. The proteinuria evaluation in both the pediatric patients (OR = 57.71, 95% CI: 7.21−461.82) and the adult patients (OR = 6.38, 95% CI: 2.51−16.24) emphasized the good effect of antiviral therapy on adult patients and pediatric patients ([Fig 4](#pone.0227532.g004){ref-type="fig"}). There was no heterogeneity in the CR rate in trials with pediatric patients (I^2^ = 0%, *P* = 0.82) or adult patients (I^2^ = 0%, *P* = 0.43), which shows the relationship between age and heterogeneity.

![CR with antiviral therapy in adult patients and pediatric patients.\
OR: odds ratio; CR: complete remission.](pone.0227532.g004){#pone.0227532.g004}

### 3.4 Subgroup analysis of groups at the 12-month follow-up {#sec019}

Three trials (n = 100) mentioned the proteinuria remission rate at the 12-month follow-up, and the results showed that the CR (OR = 12.89, 95% CI: 1.56−106.41) of proteinuria was obviously higher in the antiviral treatment group than in the control group. Heterogeneity using the I^2^ statistic with a random effect model was I^2^ = 69%, *P* = 0.04, and the test for subgroup difference was *P* = 0.86 ([Fig 5](#pone.0227532.g005){ref-type="fig"}).

![CR and CR+PR with at the 12-month follow-up.\
OR: odds ratio; CR: complete remission; PR: partial remission.](pone.0227532.g005){#pone.0227532.g005}

4. Effects on the eGFR {#sec020}
----------------------

The renal function of patients was observed in four of the seven trials during the follow-up. Anti-viral therapy did not affect the eGFR (MD = 5.74, 95% CI: -4.24−15.73), and the heterogeneity was I^2^ = 44% with a fixed-effect model ([Fig 6](#pone.0227532.g006){ref-type="fig"}). The sensitivity analysis revealed that heterogeneity was mainly impacted by the studies by Sun's study\[[@pone.0227532.ref017]\] ([S4 Fig](#pone.0227532.s004){ref-type="supplementary-material"}).

![eGFR in antiviral therapy.\
OR: odds ratio.](pone.0227532.g006){#pone.0227532.g006}

5. Clearance of HBeAg in antiviral therapy {#sec021}
------------------------------------------

Four trials, including 142 cases, investigated the impact of antiviral therapy on HBeAg clearance in HBV-GN patients. We evaluated HBeAg clearance after antiviral therapy, and the heterogeneity using the I^2^ statistic was 63%, *P* = 0.05. The test for the overall effect was *P*\<0.00001 with a random effect model ([Fig 7](#pone.0227532.g007){ref-type="fig"}). HBeAg significantly decreased after antiviral therapy (OR = 27.08, 95% CI: 3.71−197.88). A sensitivity analysis was performed and showed that the study by Tang's study\[[@pone.0227532.ref019]\] was the main factor impacting the results. ([S5 Fig](#pone.0227532.s005){ref-type="supplementary-material"})

![HBeAg clearance in antiviral therapy.\
OR: odds ratio.](pone.0227532.g007){#pone.0227532.g007}

6. Publication bias {#sec022}
-------------------

Publication bias may exist when no significant findings remain unpublished thus artificially inflating the apparent magnitude of an effect. Begg's test and Egger's test were performed to assess the publication bias for total remission of proteinuria and suggested the absence of publication bias (Begg's test: *P* = 0.230; Egger's test: *P* = 0.191).

7. Adverse events {#sec023}
-----------------

Six trials mentioned side effects during treatment, including 201 patients. Three studies were treated with IFNs (n = 95), and adverse events were encountered after approximately 3 months of therapy and were mainly flu-like illnesses and pains. Later, side effects appeared after 6 months of therapy were mainly psychiatric problems. The most common events were flu-like syndrome (50/95, 52.6%), fever (26/95, 27.3%), fatigue (27/95, 28.4%) and various kinds of pains (46/95, 48.2%), including myalgia (n = 30), headaches (n = 28), abdominal pain (n = 2) and arthralgia (n = 8). The above symptoms were not serious and subsided spontaneously or were relieved by analgesics. The psychiatric symptoms (21/95, 22.1%), such as anxiety and loss of interest (n = 6), insomnia (n = 8), depression (n = 4) and suicidal ideation (n = 3). These side effects disappeared quickly after reducing the dose of IFNs. Other symptoms were rare including anorexia, nausea, chills, neutropenia and thrombocytopenia. Compared with IFNs, the side effects in patients treated with NAs (n = 70) were fewer, and the adverse events observed in the remaining three trials seemed to be random with no specific symptoms mentioned.

Discussion {#sec024}
==========

Our meta-analysis showed that most patients with HBV-GN were successfully treated with antiviral therapy, and the summary estimate for the OR of proteinuria decrease at the end of therapy was 11.64 (95% CI: 5.17−26.21). Similar results were reported in previous meta analyses\[[@pone.0227532.ref004],[@pone.0227532.ref006],[@pone.0227532.ref007],[@pone.0227532.ref009],[@pone.0227532.ref010]\]. Compared with CR, the quantity of PR could not reflect the treatment effects, so our study focused on total remission (CR+PR) and CR. From the numerical results, we found that the included patients all experienced benefits in total remission and CR. However, the CR statistics showed larger heterogeneity than did total remission. This finding indicated that the clinical efficacy of these trials differed. To make accurate decisions regarding treatment for different groups of patients and explore the sources of heterogeneity, we carried out subgroup and sensitivity analyses to identify the influencing factors. In the prespecified subgroup analysis, the test for differences among age subgroups showed a moderate difference with *P* = 0.06, and the OR for pediatric patients was 57.71, which was much larger than that of adult patients (OR = 6.38). Heterogeneity decreased to I^2^ = 0% in both pediatric and adult patients. The results showed that pediatric patients were more sensitive to antiviral therapy than adults, which illustrated that children recovered more easily. Subgroup differences in drug type (*P* = 0.10) were not very significant. IFNs were more effective than NAs. This result was not inconsistent with Yang's study\[[@pone.0227532.ref010]\], which proved IFNs and NAs were equally effective at causing proteinuria remission. However, Yang's study\[[@pone.0227532.ref010]\] only focused on MN (membranous nephropathy) patients, we considered different research subjects might lead to conflicting conclusions. Furthermore, the study type and follow-up duration subgroups did not differ in terms of results. The sensitivity analysis showed that Sun's study\[[@pone.0227532.ref017]\] and Panomsak's study\[[@pone.0227532.ref020]\] were the main source of influence on CR. Renal pathological examination in these studies revealed that the pathologic types were various, IgA nephropathy had a lager proportion. While, almost all of the HBV-GN patients presented MN in other studies, except 2 patients in Bhimma's study\[[@pone.0227532.ref018]\] were MPGN (Mesangial Proliferative Glomerular Nephritis), which may be the reason for influencing heterogeneity.

The effect of antiviral therapy on eGFR was not obvious. The first reason for poor efficacy was age because the standards for eGFR for adult patients and pediatric patients are not the same, so they are not suitable for combining together for analysis. Second, body weight and sex could affect eGFR, and the patients that were included may have been heterogeneous with respect to these indicators. In addition, antiviral drugs associated with nephrotoxicity, such as adefovir dipivoxil, tenofovir and IFNs, should also be taken into consideration. These are excreted through the kidney, and high concentrations of both the drugs and their metabolites can cause renal injury. Izzedine's study\[[@pone.0227532.ref024]\] demonstrated that adefovir dipivoxil (120 mg/d) could increase the serum creatinine level by 44 μmol/L in HIV-infected patients. Kara AV's study\[[@pone.0227532.ref025]\] found that tenofovir could decrease the eGFR and that the change in eGFR was not statistically significant. The after sensitivity analysis also confirmed that Sun's study\[[@pone.0227532.ref017]\], which chose lamivudine as an intervention, has a great influence on the heterogeneity. In addition, inconsistency of renal pathologic types may also be a factor. Wang et al\[[@pone.0227532.ref009]\] performed a meta-analysis and decleared that NA monotherapy could protect renal function and preventing Scr (Serum creatinine) elevation. However, our results didn't show significant improvement in renal function, especially under treatment of NAs.

Our results showed that antiviral therapy could increase HBeAg seroconversion. Other meta analyses also showed the same results\[[@pone.0227532.ref006],[@pone.0227532.ref007],[@pone.0227532.ref009],[@pone.0227532.ref010]\]. HBeAg seroconversion marks the immune-active phase of disease transition to the inactive carrier state\[[@pone.0227532.ref026]\]. Among the included trials, Tang's study\[[@pone.0227532.ref019]\] made the results heterogeneous. The sample size of their trial was smaller, and we considered that the results were more likely to be biased. Serum HBV DNA is a sensitive quantitative index that could facilitate the monitoring of response to treatment. The National Institutes of Health Workshop proposed an arbitrary serum HBV DNA level of 10^5^ copies/mL to differentiate chronic hepatitis B from an inactive carrier state. Another study claimed that 33% of patients with HBeAg-negative chronic hepatitis had HBV DNA levels that were persistently above 10^5^ copies/mL\[[@pone.0227532.ref027],[@pone.0227532.ref028]\]. According to these data, we considered that in terms of reflecting the disease condition, HBeAg clearance could replace serum HBV DNA to some extent. Two trials\[[@pone.0227532.ref018],[@pone.0227532.ref019]\] included in our study mentioned serum HBV DNA as an outcome indicator, but they did not provide concrete values; they only described the numbers of patients that had a decrease in serum HBV DNA. For the above reasons, we did not evaluate the effect of drugs based on this indicator.

The incidence of adverse reactions for IFNs was greater than for NAs. The side effects of the groups were different from each other, but most of them were within the tolerable range. Reducing the dose could result in the relief of symptoms.

Antiviral drugs were initially intended to treat HBV infection, but the present findings proved these have a curative four major mechanisms: (1) HB immune complexes of macromolecules were deposited in the mesangial area and sub-endodermis, leading to different pathological types. One is circulating immune complexes of viral antigen and host antibody, and the other is in situ immune complexes involving viral antigens bound to glomerular structures\[[@pone.0227532.ref029]\]. Previous studies have reported that HBeAg is the primary antigen related to subepithelial deposits in patients with HBV-MN\[[@pone.0227532.ref030],[@pone.0227532.ref031]\]. Takekoshi et al\[[@pone.0227532.ref032]\] supported the view that immune complexes, especially those containing HBeAg, were essential in the pathogenesis of HBV-GN.

\(2\) HBV infection of nephrocytes induces a cytopathic effect\[[@pone.0227532.ref033]\]. Thus, the hypothesis does not have a definite answer and needs further evidence.

\(3\) Virus-induced specific immunological effector mechanisms (specific T lymphocyte or antibody) that damage the kidney, which induces pathologic damage (such as cell apoptosis and proliferation) and HBV replication in renal tissue. Host immunodeficiency and virus variation are thought to be the most subtle contributions to persistent HBV infection.

\(4\) HBV in tissue could express viral proteins or pro-inflammatory cytokines, resulting in renal injury\[[@pone.0227532.ref034]\].

Human HBV is a small, enveloped, primarily hepatotropic DNA virus\[[@pone.0227532.ref035]\]. NAs can suppress viral replication by inhibiting the activity of HBV polymerase in the infected liver, but they cannot eliminate existing viruses or eradicate HBV cccDNA\[[@pone.0227532.ref036]\]. IFNs bind to cellular receptors and induce large numbers of genes termed IFN-stimulated genes (ISGs). ISGs are multifunctional and can inhibit HBV replication at different stages: they can suppress cccDNA transcription and accelerate cccDNA decay, inhibit the activity of HBV enhancers, influence posttranscriptional control of HBV replication, and inhibit HBV nucleocapsid formation. Furthermore, IFNs can also activate antiviral enzymes and stimulate an immunomodulatory effect\[[@pone.0227532.ref037]\].

In summary, pediatric patients were sensitive to antiviral drugs, which could be used fairly easily to mitigate proteinuria, and they required a shorter duration of treatment than did adults. Therefore, we think that further implementation of randomized controlled trials on pediatric patients would be straightforward. A comparison between IFNs and NAs demonstrated that IFNs were more effective, but the incidence of side effects was higher for IFNs than for NAs. We conclude that an individualized therapy program considering treatment efficacy and side effects is the best option for patients.

Several limitations in our meta-analysis should be considered. First, the quality of our analysis could be improved by a larger sample size and longer follow-up. Observational studies are not the best study design to answer intervention questions because of bias and confounding, the effects of which are unpredictable and may result in an overestimate, an underestimate, or true estimate of the effect. The limited number of studies available and patients enrolled in each study reduced the strength of our final conclusions. Second, dosage and treatment duration for drug administration and the follow-up duration might have influenced the clinical trial data. Third, patients enrolled in our study had a variety of renal lesion types. Because the clinical results of patients with renal puncture pathology are unavailable, no further subgroup analysis could be performed. Finally, trials in our meta-analysis were all in English and conducted in Asian countries and mostly limited to China. This geographic concentration is probably the reason for the high prevalence of HBV infection in these countries. As a result, our conclusions concerning the efficacy and safety of antiviral treatments may not apply to European or American patients.

Conclusion {#sec025}
==========

In summary, some broad conclusions can be drawn. Our results strengthen the evidence that antiviral therapy is effective in antiviral treatment groups compared to control groups. It was particularly effective in attaining remission of proteinuria and improving HBeAg clearance but failed to improve the eGFR. Antiviral treatment has a definite therapeutic effect on children, and IFNs seem more effective than NAs. However, NAs showed fewer adverse reactions than IFNs, so we tend to choose drugs based on a patient\'s specific condition. Follow-up duration and study type did not have major impacts on the results. Our study highlights the need for randomized controlled trials in the area of HBV-GN, so we can evaluate the best antiviral approach.
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This interesting meta-analysis was evaluated by the reviewers and the feedback was positive regarding the acceptance of their manuscript in PLOS ONE. Reviewers asked for minor comments which should be considered by the authors in the revised manuscript. One of the reviewers raised a major concern regarding the \"additional outcome measure of suppression or clearance of hepatitis B DNA\" which should be carefully take into consideration by the authors. 

We would appreciate receiving your revised manuscript by Oct 11 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Heidar Sharafi

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2.  Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Additional Editor Comments:

In my evaluation, I found the study well-designed and -presented and can have great contribution in literature and clinical management of patients however, I found some additional points to be corrected for improvement of manuscript presentation. Please find them:

1\. Authors used \# to show the authors with equal contribution however, only one author\'s name tagged with \#.

2\. In the first line of abstract it has been pointed to \"corticosteroid\" while there is nothing on corticosteroids in the study design and results.

3\. In abstract, \"proteinuria 18 (OR=10.48, 95% CI: 4.60�23.89, I2=0%, P=0.80)\". Is the P for heterogeneity or overall effect? It should be clarified.

4\. I guess the results for eGFR should be the mean difference of eGFR instead of OR.

5\. In introduction, \"where four studies\[4,6,7\]\" while 3 study have been cited.

6.  In Methods, \"In the absence of statistically significant heterogeneity I2\>50%\" I2 \>50% means significant heterogeneity.

7\. Page 11, Line 14, \"Eight studies were conducted evaluating\" 7 or 8?

8. Page 12, Line 1, \"fixed model\" or fixed-effect model?

9. Page 12, Line 4, heterogeneity was highly significant (I2=0%, P=0.80). I2=0% and significant heterogeneity?

10. Page 12, Line 10, \"We conducted a sensitivity analysis of all studies (Fig 5).\" but 6 studies entered in sensitivity analysis.

11. Page 12, Lines 12-15 and in Figure 4, these overall effects caused by repeated inclusion of studies in the meta-analysis. I recommend to exclude it from manuscript and from the Total OR (95% CI) in the bottom part of forest plot in Figure 4. The same can be true for Figure 8 and Figure 9 with inclusion of studies multiple times make a false total overall effect.

12\. Page 14, \"Meanwhile, in trials with IFNs, the treatment group was not obviously affected (P\<0.00001, I2=100%). Are they talking about heterogeneity? The heterogeneity is high with I2=100.

13\. For pooled effect of clearance of HBeAg in antiviral therapy, the I2=63% and yet using fixed effect model.

14\. My main concern is the discussion. It is currently concentrated on the results and less discuss the findings. There are much talked about heterogeneity while it is a technical issue while they should concentrate on overall effect of the pooled analysis. They added some information on the mechanism of HBV-GN, I am not against presentation of such information however much is not needed and there is lack of information on how significant is the treatment of HBV-GN and what is the recommendation of authors for treatment of HBV-GN based on the results of meta-analysis. Moreover, in a paragraph, the limitations have been included however, I would like to ask authors to highlight what are the strengths of their study and how it is changing the current knowledge while few meta-analysis have been published even recently (2016).

15\. In PRISMA flow diagram, \"115 records after duplicates removed\". Are these 115 were duplicates excluded? It is really confusing in the current drawing.

16\. There is an additional unnecessary Total effect in Figure 11 can be excluded.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: A number of sections in this document need to be reviewed and improved English syntax and lexicon is advised

Wording: Page 8 line 11 should be changed from \"primary aftermath measures\" to \"primary outcome measures\"

There should be an additional outcome measure of suppression or clearance of hepatitis B DNA\\\\

The current population estimate on page 9 line 9 is there are 292 million people with Hepatitis B today world health organization and Polaris

The authors need to highlight that there are two types of tenofovir: TDF and TAF

tenofovir is no capitalized

The letter B should be capitalized throughout the manuscript when discussing the HBV or hepatitis B

glomerulonephritis does not need to be capitalized

adefovir and tenofovir analogues are known nephrotoxins

Did the authors look at nephrotoxicity risk in these manuscripts? And effect on GFR ? this may partially explain the lack of change in GFR?

Reviewer \#2: Dear Editor

Thanks for inviting me to review the manuscript PONE-D-19-20164 entitled \"Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: a meta-analysis\". The subject is novel with a correct methodology, and its manuscript is well-written. My minor comments to the authors are as follow:

\- There are some minor writing mistakes in the manuscript. (HVB-GN \>\>\> HBV-GN, Mesh \>\>\> MeSH, and\...) Please read the manuscript carefully to find and correct them.

\- There is no need to use thirteen figures to show the results. You can remove some unnecessary figures or move them into supplements section. Figure one in unnecessary you can move it to the supplements. Showing the publication bias in a figure is not necessary.

\- There is no need to acknowledge the language editor institute.

Regards

Reviewer

Reviewer \#3: This is a well-written paper out of good work. Although the size of the data is not large, it reaffirms previous information on the efficacy of anti-HBV treatments on HBV-GN.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Robert G Gish

Reviewer \#2: Yes: Hamidreza Karimi-Sari

Reviewer \#3: Yes: Amir Ali Sohrabpour

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0227532.r002

Author response to Decision Letter 0

9 Oct 2019

Dear Editors and reviewers：

Thank you for your letter of comments and for the referee's comments concerning our manuscript entitled "Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: a meta-analysis". We have studied all comments carefully and have made corrections. We have send the revised manuscript and revised portion were marked in red. We really hope to meet with your approval.

###### 

Submitted filename: Response to reviewers.docm

###### 

Click here for additional data file.

10.1371/journal.pone.0227532.r003
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Sharafi

Heidar

Academic Editor

© 2020 Heidar Sharafi
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Heidar Sharafi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

7 Nov 2019

PONE-D-19-20164R1

Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: a meta-analysis

PLOS ONE

Dear Dr Yang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

After initial evaluation of revised manuscript, I decided to send the manuscript for peer-review again to improve its scientific presentation to reach a level aligned for publication in PLOS ONE. One of the main points is proofing the English expression of manuscript before acceptance. Authors can ask a colleague expert in English writing or a professional English editing service to improve their manuscript English expression.

We would appreciate receiving your revised manuscript by Dec 22 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Heidar Sharafi

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

I have few minor comments on the revised manuscript:

1\. Conclusion of abstract should be concise.

2\. Page 3, Line 18, use \"nucleos(t)ide analogs (NAs)\" instead of \"nucleoside analogs (NAs)\".

3\. I didn\'t find S1 Table.

4\. It was stated \"Heterogeneity between data sources was noted in the CR rate of all trials (I2=23%, P=0.26) and CCTs (I2=9%, P=0.36).\" while based on I2 there is no significant heterogeneity between studies. Page 12, Lines 9-11

5\. What is \"(I2=0%\<50%, P=0.77)\"? Page 12, Line 14

6\. Page 12, Lines 11-12, \"Our analysis determined that the study by Lin et al\[17\] was the source of heterogeneity.\", based on Figure 4, I expect the study by Fang et al to cause heterogeneity.

7\. Figure 3, the scale of first plot and the two next plots should be the same. all 0.001-1000 or 0.01-100.

8\. Regarding the sensitivity analysis plots, why the scales are not aligned with the results of meta-analysis? For example, in figure 4, the OR is 2.58 while I expect an OR 11.64 based on the meta-analysis. This is true for other sensitivity analysis plots as well.

9\. Figure 7, in caption of plot, the OR\>1 should favours experimental and OR\<1 should favours control.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

Reviewer \#4: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: No

Reviewer \#4: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: Thanks for revising your work. Almost all of my comments are addresses, but a minor issue is still remained in the manuscript. Eleven figures are not recommended in a paper. You can move 4 other figures (2, 4, 9, 11) to the supplementary materials (supporting information).

Regards

Reviewer

Reviewer \#4: Dear Associated Editor

I am very thankful for giving me the opportunity to review the manuscript entitled "Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: a meta-analysis" and evaluate it for publishing in PLOS ONE. This manuscript has been revised once. I appreciate the efforts authors put into this work. However, I would like to mention some major point for authors:

1\. The manuscript needs writing edit for English language:

a\) Improve overall readability

b\) Use shorter sentences

c\) Pay attention to punctuation (for instance in the third line of introduction dot and comma used together.)

d\) There are several grammatical errors in the manuscript (As an example the first sentence of the second paragraph of introduction has totally wrong structure)

2\. Authors declared that there were several meta-analysis in this field and there were published before 2011 and that is the reason they performed this study. Only two included studies published after 2011, do they have great impact on the results and evidences?! What is the benefit of your study?

3\. Mention the exact PICOS of the study at the end of the introduction section.

4\. Mention the exact time you performed your search, in the methods section.

5\. Provide search strategy for at least one database.

6\. Why did you searched PUBMED and MEDLINE?? When you are searching PUBMED you are searching MEDLINE, too.

7\. Provide more information about covering grey literature. How did you cover this and which conferences did you check.

8\. Did you consider any specific language in the search? Four of seven included studies are from China.

9\. Write "Eligibility criteria" section in an organized way. It is really confusing.

10\. Mention the outcome you expected to find in the included articles, in the "Eligibility criteria" section.

11\. In "Data extraction" section, mention the exact variables you extracted from the studies. Do not use "So on".

12\. Did you pay attention to funding source of the studies? You did not mention this.

13\. Third line of "Statistical analysis" section, the sentence "In the absence of\..." can be deleted. You have discussed this further.

14\. You included seven studies. Four from China, two from other parts of Asia and one from Africa. How do you discuss this distribution?

15\. "Subgroup analysis of association between efficacy and study types" part should be totally revised. First, discuss the heterogeneity results and then report the analysis results.

16\. In "Subgroup analysis of association between efficacy and study types" section, heterogeneity of CCTs was reported twice in the 8th and 11th line with different statistics. Please rewrite this part and make it clear if they are different variables.

17\. In the second line of "Effects on eGFR" section, replace "anti-virus therapy" with "anti-viral therapy".

18\. In the fifth line of "Effects on eGFR" section, authors declared "it seems that NAs has therapeutic effect on eGFR". However, the reported confidence interval includes zero. Please clarify this part.

19\. The discussion part is written like introduction section. Study results should be discussed and compared with other studies. Discussion section needs an overall revision.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

Reviewer \#4: Yes: Maryam Tajik

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0227532.r004

Author response to Decision Letter 1

20 Dec 2019

Thank you for your kind comments on our manuscript. We have carefully revised the manuscript according to the reviewer's comments. Based on the suggestions, we have made an extensive modification on the revised manuscript.. The changes to our manuscript within the document were aslo highlighted by using red colored text.

###### 

Submitted filename: Response to Reviewers.doc

###### 

Click here for additional data file.

10.1371/journal.pone.0227532.r005
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© 2020 Heidar Sharafi
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Heidar Sharafi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

23 Dec 2019

Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: a meta-analysis

PONE-D-19-20164R2

Dear Dr. Yang,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Heidar Sharafi

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0227532.r006

Acceptance letter

Sharafi

Heidar

Academic Editor

© 2020 Heidar Sharafi

2020

Heidar Sharafi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

2 Jan 2020

PONE-D-19-20164R2

Efficacy and safety of anti-viral therapy for Hepatitis B virus-associated glomerulonephritis: a meta-analysis

Dear Dr. Yang:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Heidar Sharafi

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
